A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein

被引:76
作者
Ji, QC [1 ]
Rodila, R [1 ]
Gage, EM [1 ]
El-Shourbagy, TA [1 ]
机构
[1] Abbott Labs, Dept Drug Anal, Abbott Pk, IL 60064 USA
关键词
D O I
10.1021/ac034930n
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Immunoassays are used extensively in the quantitative analysis of proteins in plasma, urine, and other biological matrixes to support preclinical and clinical studies. Although immunoassays are both sensitive and rapid, difficulties during development of these assays are compounded by the need to have a specific antibody or antigen to the protein of interest. Furthermore, calibration curves of immunoassays are inherently nonlinear, and the technique often detects many structurally related components in addition to the analyte of interest. We have developed a novel strategy of analyzing protein concentrations in plasma by utilizing 96-well solid-phase extraction and LC-MS/MS detection of the intact protein. This strategy has been successfully applied in method development and assay validation of quantitatively analyzing protein rK5 concentrations in monkey plasma samples. Additional techniques such as precolumn regeneration and column heating were also incorporated into the assay. Total run time for each sample was similar to 15 min. An LLOQ of 99.2 ng/ mL from a sample volume of 50 muL, corresponding to only 380 fmol (3.97 ng) of the rK5 analyte being injected onto the analytical column (assuming 100% extraction recovery), was obtained. The validated linear dynamic range was between 99.2 and 52 920.0 ng/mL, with a correlation coefficient (r(2)) ranging from 0.9972 and 0.9994. The intraassay CV for this assay was between 0.6 and 3.8%, and the interassay CV was between 1.7 and 3.2%. Interassay mean accuracies were between 10 1.5 and 104.7%. The assay has proven rugged and specific and has been employed to generate data in support of preclinical studies. This strategy for rK5 assay could be used for the development of bioanalytical assays to provide preclinical and clinical support for other protein drug candidates and, furthermore, for the validation of biomarkers discovered from proteomic research.
引用
收藏
页码:7008 / 7014
页数:7
相关论文
共 18 条
  • [1] Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies
    Ardekani, AM
    Herman, EH
    Sistare, FD
    Liotta, LA
    Petricoin, EF
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (11): : 803 - 819
  • [2] Online single-step analysis of blood proteins: The transferrin story
    Bergen, HR
    Lacey, JM
    O'Brien, JF
    Naylor, S
    [J]. ANALYTICAL BIOCHEMISTRY, 2001, 296 (01) : 122 - 129
  • [3] DAVIDSON DJ, UNPUB J CLIN INVEST
  • [4] *FOOD DRUG ADM US, GUID IND BIOAN METH
  • [5] Effect of the mobile phase composition on the separation and detection of intact proteins by reversed-phase liquid chromatography -: electro spray mass spectrometry
    García, MC
    Hogenboom, AC
    Zappey, H
    Irth, H
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2002, 957 (02) : 187 - 199
  • [6] Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS
    Gerber, SA
    Rush, J
    Stemman, O
    Kirschner, MW
    Gygi, SP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (12) : 6940 - 6945
  • [7] Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
    Gygi, SP
    Rist, B
    Gerber, SA
    Turecek, F
    Gelb, MH
    Aebersold, R
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (10) : 994 - 999
  • [8] Modern strategies for protein quantification in proteome analysis: Advantages and limitations
    Hamdan, M
    Righetti, PG
    [J]. MASS SPECTROMETRY REVIEWS, 2002, 21 (04) : 287 - 302
  • [9] Jemal M, 2000, BIOMED CHROMATOGR, V14, P422, DOI 10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO
  • [10] 2-I